Skip Navigation


Annals of Oncology Advance Access originally published online on April 22, 2005
Annals of Oncology 2005 16(7):1207-1208; doi:10.1093/annonc/mdi206
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
16/7/1207    most recent
mdi206v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (18)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Sanna, G.
Right arrow Articles by Goldhirsch, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sanna, G.
Right arrow Articles by Goldhirsch, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 European Society for Medical Oncology

Letter to the Editor

Jaw avascular bone necrosis associated with long-term use of biphosphonates

The first 10% of the full text of this article appears below.

Bisphosphonates are currently used to prevent bone complications and to treat malignant hypercalcemia in patients with multiple myeloma, or bone metastases from breast and prostate cancers [1Go].

Within the last year we observed 10 patients who developed jaw bone necrosis while on treatment with zoledronic acid (Zometa®; Novartis) or pamidronate. All the patients . . . [Full Text of this Article]

G. Sanna*, M. G. Zampino, G. Pelosi, F. Nolè and A. Goldhirsch

Istituto Europeo di Oncologia, Via Ripamonti 435, 20141 Milano, Italy

(*Email: giuseppina.sanna@ieo.it)


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 The Journal of RheumatologyHome page
A. A. KHAN, G. K.B. SANDOR, E. DORE, A. D. MORRISON, M. ALSAHLI, F. AMIN, E. PETERS, D. A. HANLEY, S. R. CHAUDRY, B. LENTLE, et al.
Bisphosphonate Associated Osteonecrosis of the Jaw
J Rheumatol, March 1, 2009; 36(3): 478 - 490.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
C. D Krueger, P. M West, M. Sargent, A. E Lodolce, and A S. Pickard
Bisphosphonate-Induced Osteonecrosis of the Jaw
Ann. Pharmacother., February 1, 2007; 41(2): 276 - 284.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
G Sanna, L Preda, R Bruschini, M Cossu Rocca, S Ferretti, L Adamoli, E Verri, L Franceschelli, A Goldhirsch, and F Nole
Bisphosphonates and jaw osteonecrosis in patients with advanced breast cancer
Ann. Onc., October 1, 2006; 17(10): 1512 - 1516.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
T. Van den Wyngaert, M. T. Huizing, and J. B. Vermorken
Bisphosphonates and osteonecrosis of the jaw: cause and effect or a post hoc fallacy?
Ann. Onc., August 1, 2006; 17(8): 1197 - 1204.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. Ardine, D. Generali, M. Donadio, S. Bonardi, M. Scoletta, A. M. Vandone, M. Mozzati, O. Bertetto, A. Bottini, L. Dogliotti, et al.
Could the long-term persistence of low serum calcium levels and high serum parathyroid hormone levels during bisphosphonate treatment predispose metastatic breast cancer patients to undergo osteonecrosis of the jaw?
Ann. Onc., August 1, 2006; 17(8): 1336 - 1337.
[Full Text] [PDF]

Home page
 Mayo Clin Proc.Home page
D. Kademani, S. Koka, M. Q. Lacy, and S. V. Rajkumar
Primary Surgical Therapy for Osteonecrosis of the Jaw Secondary to Bisphosphonate Therapy
Mayo Clin. Proc., August 1, 2006; 81(8): 1100 - 1103.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
D. Errante, N. Mannucci, D. Bernardi, A. Bianco, and L. Salvagno
Comment on 'Jaw avascular bone necrosis associated with long-term use of biphosphonates'
Ann. Onc., February 1, 2006; 17(2): 350 - 352.
[Full Text] [PDF]